Immuneering Corp (IMRX) Form 8-K — Jun 15, 2026
Immuneering Corporation appointed Andrew Gengos as Chief Financial Officer and Treasurer, effective on or before July 16, 2026, succeeding Mallory Morales as principal financial officer. Mr. Gengos brings extensive experience from his previous roles as CFO at Terns Pharmaceuticals and LeonaBio, as well as strategy and corporate development experience at Amgen. The company agreed to pay Mr.
Key figures
- Base Salary
- 530000
- Option Shares
- 650000
- Effective Date
- 2026-07-16
- Bonus Target Percent
- 40%
Price after filing
1 day: -2.1%7 days: +6.0%30 days: +23.2%
Close on the filing date to close N calendar days later (from $4.19). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.